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HIV-1 transmissionimportant in HIV-1 transmission; DCs capture invading HIV-1 through the
interaction of the gp120 oligosaccharides with the C-type lectin DC-SIGN and migrate to the lymphoid tissues
where HIV-1 is transmitted to T cells. Thus, the HIV-1 envelope glycoprotein gp120 is an attractive target to
prevent interactions with DCs and subsequent viral transmission. Here, we have investigated whether the
structural homologue of DC-SIGN, the nematode C-type lectin Mermaid can be used to prevent HIV-1
transmission by DCs. Our data demonstrate that Mermaid interacts with high mannose structures present on
HIV-1 gp120 and thereby inhibits HIV-1 binding to DC-SIGN on DCs. Moreover, Mermaid inhibits DC-SIGN-
mediated HIV-1 transmission from DC to T cells. We have identiﬁed Mermaid as a non-cytotoxic agent that
shares the glycan speciﬁcity with DC-SIGN and inhibits DC-SIGN-gp120 interaction. The results are important
for the anti-HIV-1 microbicide development directed at preventing DC-HIV-1 interactions.
© 2008 Elsevier Inc. All rights reserved.Introduction
The development of an effective vaccine against HIV-1 remains
elusive and is an obstacle in combating HIV-1 infection. Approaches
preventing HIV-1 transmission, in particular those that target the
dendritic cell (DC)-mediated transmission of HIV-1 are very
attractive, since it precedes HIV-1 replication and thereby mutagen-
esis in the host. Moreover, our current knowledge about the
underlying process of HIV-1 transmission allows us to develop
speciﬁc preventive strategies.
The human immunodeﬁciency virus type 1 (HIV-1) envelope
glycoprotein gp120 is extensively glycosylated and contains approxi-
mately 24 potential N-linked glycosylation sites. These glycosylation
sites are occupied with glycans that form almost 50k of the gp120
molecular weight. The gp120 glycans represent high-mannose, hybrid
and complex classes and serve as ligands for different lectins (Geyer et
al., 1988). HIV-1 bindingmediated by the DC-speciﬁc C-type lectin DC-
SIGN (dendritic cell-speciﬁc ICAM-3 grabbing non-integrin; CD209)
facilitates HIV-1 transmission by DCs to T cells (Geijtenbeek et al.,
2000a,b). Moreover, internalized virus is stored in multivesicular
bodies and speciﬁcally transmitted to CD4+ T cells through infectious
synapses formed between DCs and T cells (McDonald et al., 2003).
These processes are very speciﬁc and substantially increase T cellnbeek).
l rights reserved.infection. The membrane-associated C-type lectin DC-SIGN is one of
the main players in the described establishment and dissemination of
HIV-1 and other infections (Curtis et al., 1992; Geijtenbeek et al.,
2000a,b; Arrighi et al., 2004; Lekkerkerker et al., 2004; Nabatov et al.,
2006; Zhang et al., 2006; Zhang et al., 2008). Therefore, preventing
HIV-1 interaction with DCs, and in particular DC-SIGN, might
represent a powerful method to prevent HIV-1 transmission and
infection of the host. Several strategies have been aimed at inhibiting
DC-SIGN function using soluble carbohydrates or antibodies against
DC-SIGN. However, a more efﬁcient method might be to target gp120
with speciﬁc inhibitors in order to prevent DC-SIGN binding.
The importance of gp120 glycans for the many aspects of HIV-1
infection makes them suitable targets for anti-HIV-1 treatment or
prophylaxis (Balzarini, 2007; Witvrouw et al., 2005). The ability of
different sugar-binding proteins to neutralize HIV-1 in vitro has been
shown for a number of lectins (reviewed in (Balzarini, 2006)). Of
special interest are the lectins that resemble the structure and
speciﬁcities of the natural HIV-1-binding lectins such as DC-SIGN.
Mermaid is a novel Ca2+-dependent mannose-speciﬁc C-type
lectin that is exclusively secreted onto the posterior, bacterium-
associated region of Laxus oneistus cuticle. This C-type lectin mediates
bacterial symbiont aggregation on theworm cuticle. The carbohydrate
recognition domain of this mannose-binding protein is structurally
and functionally similar to the one of human DC-SIGN (Bulgheresi et
al., 2006; Zhang et al., 2006).
In the current study we have demonstrated that Mermaid in the
form of a biological chimera (Zhang et al., 2008) is able to block DC-
mediated HIV-1 transmission by preventing DC-SIGN binding to HIV-
Fig. 2. Mermaid glycan speciﬁcity. Mermaid and DC-SIGN were tested for their
speciﬁcity with a panel of biotin-labeled glycans: galactose (Gal); mannotriose (Man3)
and glucitol (Gluc) for Mermaid and DC-SIGN, respectively. Lectin binding was also
determined in the presence of EGTA. Error bars represent SD. Background levels
(without DC-SIGN-Fc) were 0.06±0.01. The results shown are representative of at least
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microbicides, which act by blocking DC-SIGN-mediated HIV-1
transmission.
Results
Mermaid blocks binding of DC-SIGN to gp120 and ManLAM
Mermaid is a C-type lectin and its structure has high similarity
with human DC-SIGN, suggesting that it might interact with similar
oligosaccharide structures as DC-SIGN (Bulgheresi et al., 2006). Since
HIV-1 targets DC-SIGN on DCs for viral transmission to T cells
(Geijtenbeek et al., 2000a), we investigated whether Mermaid inhibits
the interaction between DC-SIGN and HIV-1 gp120. Soluble DC-SIGN
interacted with both HIV-1 gp120 and its mycobacterial ligand
ManLAM (Geijtenbeek et al., 2003) (Fig. 1A). Preincubation of HIV-1
gp120 and ManLAM with Mermaid signiﬁcantly inhibits the interac-
tion of the structures with DC-SIGN (Fig. 1A). The inhibition by
Mermaidwas dose-dependent (IC50 ~ 8.8 and 10.7μg/ml for gp120 andFig. 1. Mermaid inhibits binding of DC-SIGN to pathogenic structures. DC-SIGN-Fc
binding to gp120 and ManLAM was measured in the absence and presence of Mermaid
(20μg/ml) (A) Binding of DC-SIGN-Fc to gp120 (B) andManLAM (C) wasmeasured in the
presence of mermaid (diamonds) or mannan (triangles). Error bars represent SD. The
results shown are representative of at least three independent experiments.
three experiments.ManLAM, respectively) and to background levels at the highest
Mermaid concentration. The inhibition was similar to that of the
known DC-SIGN inhibitor mannan (IC50 ~ 5.3 and 4.8μg/ml for gp120
and ManLAM, respectively) (Figs. 1B and C). These data strongly
suggest that Mermaid competes with DC-SIGN for binding to the
carbohydrate structures on gp120 and ManLAM.
Mermaid and DC-SIGN share glycan speciﬁcity
To clarify how Mermaid inhibits of DC-SIGN interactions with
mannose-containing pathogenic ligands, we compared the speciﬁcity
of the two C-type lectins using synthetic glycoconjugates linked to a
biotinylated polyacrylamide: galactose (Gal), trimannose (Man3) and
glucitol (Gluc) as a negative control. DC-SIGN interacted with Man3,
but not with Galactose (Fig. 2). Mermaid also bound to Man3 and the
interactionwas blocked with the calcium chelator EGTA. In contrast to
DC-SIGN, Mermaid also exhibited speciﬁc binding to galactose that
was blocked by EGTA (Fig. 2). Both Mermaid and soluble DC-SIGN did
not bind to the control glucitol. Thus, Mermaid interacts with similar
mannose-binding carbohydrates as DC-SIGN.
Mermaid blocks binding of gp120 to DCs
Cellular DC-SIGN has a higher avidity for HIV-1 gp120 than soluble
DC-SIGN due to cluster formation (Cambi et al., 2005). Therefore, we
investigated whether Mermaid binding to gp120 inhibits the gp120
interaction with cellular DC-SIGN expressed by Raji transfectants.
CellularDC-SIGN interactedwithHIV-1 gp120 (Fig. 3). Preincubation of
HIV-1 gp120-coated beads with Mermaid strongly decreased binding
to cellular DC-SIGN expressed by Raji transfectants (Fig. 3). HIV-1
gp120 binding to immature DCs is mediated by DC-SIGN (Geijtenbeek
et al., 2000a). Mermaid inhibited HIV-1 gp120 binding to DCs to the
level of soluble DC-SIGN (Fig. 3), whereas EGTA inhibited the
interaction more strongly. This binding assay is based on the high
avidity interaction between DCs and gp120-coated beads and our data
suggest that inhibition by targeting gp120 is less efﬁcient than by the
direct inhibition of DC-SIGN using EGTA. Moreover, it is possible that
other receptors are also involved in the gp120 binding. These data
demonstrate that Mermaid inhibits HIV-1 gp120 binding to DC-SIGN
expressed by both transfectants and immature DCs.
Mermaid speciﬁcally blocks DC-SIGN mediated transmission
DC-SIGN binding to HIV-1 leads to viral transmission to T cells
(Geijtenbeek et al., 2000a). Therefore, we investigated whether
Fig. 4. Pre-treatment of virus with Mermaid reduces DC-SIGN-mediated HIV-1
transmission on DCs. (A) Serially diluted Mermaid (diamonds) or DC-SIGN-Fc (squares)
were preincubated with HIV-1-eGFP-BaL. Alternatively, Raji-DC-SIGN cells were
preincubated with mannan (triangles). Next, Raji-DC-SIGN cells were incubated for
2hours with virus, washed and added to CCR5 expressing Jurkat cells. Virus infection
wasmonitored by eGFP ﬂuorescence in the Jurkat cells. The results are plotted with bars
as medians of data for three samples±SD (n=3). The data are representative of three
independent experiments. (B) HIV-1 JR-CSF was preincubated with Mermaid and added
to DCs and washed after 2hours of incubation when CD4+ T cells were added. Changes
in viral replication transmission (trans) experiments were followed in time. T cells and
DCs alone (T cells and DC in the plot, respectively) were taken as a control infectionwith
or without adding Mermaid. Virus replication was monitored by p24 analysis in the
culture supernatant. Data are mean±SD of triplicate points (n=3). The data are
representative of two independent experiments.
Fig. 3. Soluble DC-SIGN and Mermaid decrease binding of gp120 coated ﬂuorescent
beads to DC and Raji-DC-SIGN. Fluorescent gp120 coated beads were preincubated with
inhibitor Mermaid (300μg/ml), DC-SIGN-Fc (300μg/ml) and EGTA (10mM). The beads
were added to dendritic cells (DC), Raji control transfectants (Raji) or expressing DC-
SIGN (Raji-DC-SIGN). Percentages of cells binding gp120 beads are presented. The
results shown are representative of two independent experiments.
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was efﬁciently transmitted to T cells by DC-SIGN (Fig. 4A). Strikingly,
HIV-1 preincubation with Mermaid abrogated HIV-1 transmission
mediated by DC-SIGN in a concentration dependent manner
(IC50~3.1μg/ml). Notably, soluble DC-SIGN did not prevent HIV-1
transmission by Raji-DC-SIGN, whereas direct block of DC-SIGN by
mannan inhibited the transmission efﬁciently (Fig. 4A). These data
strongly suggest that Mermaid is an inhibitor of DC-SIGN-mediated
transmission of HIV-1.
Next, we assessed the ability of Mermaid to block transmission of
HIV from DCs to CD4+ T cells. DCs were incubated with HIV-1 and T
cells were added after 2hours without washing. As demonstrated, DCs
enhanced infection of T cells (Fig. 4B). Strikingly, preincubation of
HIV-1 with Mermaid inhibited HIV-1 transmission to a similar level
as Tcell infection alone, demonstrating thatMermaid binding to HIV-1
prevents DC-SIGN-mediated transmission (Fig. 4B). Mermaid itself did
not prevent T cell infection, strongly suggesting that it prevents HIV-1
infection of T cells by inhibiting DC-SIGN-mediated transmission.
Moreover, we did not observe any apoptosis of T cells and DCs in
presence of Mermaid (Fig. 5). Thus, Mermaid competes with DC-SIGN
for HIV-1 gp120 binding and prevents HIV-1 transmission by DC-SIGN
on DCs. In addition, Mermaid can be used safely in vitro and its activity
is not a result of cytotoxicity.
Discussion
Anti-retroviral treatment is the best option for long-lasting HIV-1
suppression and, subsequently, for reduction of morbidity and
mortality. However, current drugs do not eradicate HIV-1 infection
and lifelong treatment might be needed (Simon et al., 2006). On the
other hand, classical approaches to vaccine development have not
yielded a HIV/AIDS vaccine yet (Robinson, 2007). Thus, new strategies
need to be developed to reach signiﬁcant progress in anti-HIV therapy
or prevention. Development of topical agents (microbicides) in the
form of gels and creams preventing sexually transmitted infections is
one of the most growing new anti-HIV-1 approaches (van de Wijgert
and Shattock, 2007).
The importance of gp120 glycosylation in viral physiology suggests
the possibility of targeting the glycosylation of HIV-1 (Balzarini, 2007;
Witvrouw et al., 2005). The gp120 glycosylation-speciﬁc neutralizing
monoclonal antibody 2G12 is one of the few known antibodies that
are able to neutralize broad spectrum of HIV-1 strains, strongly
supporting the idea of the anti-glycosylation approach in anti-HIVtherapy (Trkola et al., 1996; Sanders et al., 2002). Thus identiﬁcation of
new compounds that prevent infection remains an current challenge
in HIV-1 therapy.
The current study focuses on the anti-HIV effect of the recently
identiﬁed lectin Mermaid, which has been shown to share structural
features with DC-SIGN (Bulgheresi et al., 2006). In particular we were
interested in the ability of Mermaid to inhibit DC-SIGN-mediated
HIV-1 transmission of DCs to T cells, one of the ﬁrst events in HIV
transmission from person-to-person in sexual intercourse (van Kooyk
and Geijtenbeek, 2003). Our data strongly suggest that Mermaid has
a similar binding speciﬁcity for mannose-containing carbohydrates as
DC-SIGN, since both interact with similar ligands and Mermaid
prevented DC-SIGN binding to ManLAM and gp120.
DC-SIGN expressed by DCs or transfectants captures HIV-1 and
increases transmission to T cells (Geijtenbeek et al., 2000a). Here we
show thatMermaid is able to block this transmissionwithout affecting
the viability of the Tcells. Therefore,Mermaid prevents HIV binding by
DC-SIGN and subsequent transmission to T cells in vitro.
The ability of Mermaid to block DC-SIGN recognition and binding
of gp120 suggests that these two lectins may compete for common
binding sites. We compared the sugar-speciﬁcity of DC-SIGN and
Fig. 5. Mermaid does not cause apoptosis of the DCs and CD4+ T cells. The level of 7-
AAD staining was analyzed by FACS for DCs (A) and CD4+ T cells (B) incubated with
Mermaid (grey contour) or in culture medium (thick line). The dotted line corresponds
to CD4+ T cells incubated with Mermaid and sodium azide (as a positive control). The
data are representative of two independent experiments.
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in their common ability to bind mannose rich oligosaccharide sugars.
The signiﬁcant decrease of the binding to glycans in the presence of
EGTA suggests that the binding to these sugars is Ca2+ dependent,
which is typical of C-type lectin. In contrast to DC-SIGN, Mermaid has
also speciﬁcity for galactose residues. These data suggest that
although similar, the C-type lectins do not have identical carbohydrate
recognition proﬁles.
DCs capture HIV-1 particles at the periphery and transport
them to T cell areas, where HIV-1 efﬁciently infects T cells.
Therefore, we investigated the ability of Mermaid to prevent DC-
mediated transmission. Mermaid inhibited gp120 binding to DCs.
Notably, the inhibition was similar to that observed with soluble
DC-SIGN, but less than observed with EGTA, suggesting that
Mermaid speciﬁcally blocks DC-SIGN binding but not the interac-
tion of HIV-1 with other HIV-1 attachment receptors such as
syndecan-3 (de Witte et al., 2007). In agreement with the
inhibition of HIV-1 binding, Mermaid also inhibited DC-mediated
HIV transmission. In contrast, we did not observe inhibition of
HIV-1 transmission using soluble DC-SIGN, which might be due to
a lower afﬁnity than Mermaid for gp120. Mermaid did not
signiﬁcantly inhibit direct T cell infection, further supporting our
data that Mermaid inhibits DC-SIGN-mediated transmission but not
HIV-1-CD4 interactions.
Thus, we have identiﬁed Mermaid as a non-cytotoxic agent
that shares the glycan speciﬁcity with DC-SIGN, inhibits DC-SIGN-
gp120 interaction, as well as DC-mediated HIV-1 transmission to
CD4+ T cells in vitro. As a potential microbicide, Mermaid will
attach to the virus upon entry and thereby prevent capture by
DCs and subsequent transmission. Further experiments shouldalso focus on the immunogenicity of Mermaid, as its limited
identity with DC-SIGN, which might induce inﬂammatory
responses. In conclusion, our data strongly suggest that a soluble
C-type lectin such as Mermaid might be an attractive anti-HIV-1
microbicide.
Materials and methods
Abs, natural and synthetic glycoconjugates
The mAb anti-DC-SIGN antibody blocking lectin speciﬁc binding
(mAbs AZN-D1) was used as described earlier (Geijtenbeek et al.,
2002). Mannan puriﬁed from Saccharomyces cerevisiae and recombi-
nant HIV-1SF2 gp120 expressed in CHO cells were obtained from
Sigma-Aldrich (St. Louis, MO, USA) and the AIDS Resource Founda-
tion (Rockville, MD, USA), respectively. Synthetic glycoconjugates
were obtained from Syntesome (Munich, Germany) and comprised
galactose (Gal); mannotriose (Manα 1-3(Manα1-6)Man; Man3) or
Glucitol multivalently linked to a biotinylated polyacrylamide carrier.
The biologically modiﬁed chimera of Mermaid with His-tag tail was
obtained and puriﬁed as described previously (Bulgheresi et al.,
2006).
Soluble DC-SIGN-Fc binding ELISA
DC-SIGN-Fc consists of the extracellular portion of DC-SIGN (aa
residues 64–404) fused at the C-terminus to a human IgG1- Fc
fragment as previously described (Geijtenbeek et al., 2002). The
DC-SIGN-Fc binding assay was performed as follows. Glycoconju-
gates (gp120 or ManLAM) were coated onto ELISA plates at 2 (for
serial dilution experiment) or 5μg/well; and coating took place for
18h at room temperature, followed by blocking with 2k BSA for
30min at 37°C in TSM (20mM Tris-HCl (pH 7.4) containing
150mM NaCl, 1mM CaCl2, and 2mM MgCl2). Soluble DC-SIGN-Fc
(2μg/ml in TSM buffer) was added and the adhesion was
performed for 120min at room temperature. Unbound DC-SIGN-
Fc was washed away and binding was determined by an anti-
IgG1-Fc ELISA using a peroxidase conjugate of goat anti-human-Fc.
Speciﬁcity was determined in the presence of serial dilutions of
Mermaid or mannan.
Glycan speciﬁcity assay
The DC-SIGN-Fc chimera and Mermaid (5μg/ml) were coated in
0.2M NaHCO3 on ELISA plates (Maxisorp plate; Nunc), and incubated
overnight at 4°C. This was followed by blocking with TSM containing
1k BSA for 30minutes at 37°C before addition of the biotinylated
glycoconjugates (5μg/ml in TSM) for 2hours at room temperature; the
binding was determined by incubation of a peroxidase-labeled
streptavidin for 30minutes at room temperature. The speciﬁcity was
determined by preincubation of the sorbed DC-SIGN-Fc and Mermaid
with 10mM EGTA.
HIV-1 gp120 binding assay
Beads were prepared as previously described (Geijtenbeek et al.,
2000b). In short, streptavidin was covalently coupled to carboxylate-
modiﬁed TransFluoSpheres (488/645nm excitation/emission, 1.0μm;
Invitrogen Corp.). The streptavidin beads were incubated with
biotinylated F(ab')2 fragment goat-anti-human IgG (6μg/ml; Jackson
ImmunoResearch Laboratories Inc.) and subsequently incubated
overnight with gp120-Fc chimera.
The beads preincubated with Mermaid (300μg/ml) for 30min at
37°C in medium were added to ﬁfty thousand DC and incubated
additional 40min, after which the cells were washed with TSM
containing 0.5k BSA. After washing, the cells were resuspended in
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cytometry (BD Biosciences).
Cells
Immature DCswere cultured frommonocytes in the presence of IL-
4 and GM-CSF (500 and 800U/ml, respectively; Schering-Plough,
Brussels, Belgium). At day 7, the phenotype of the cultured DC was
conﬁrmed by ﬂow cytometric analysis.
The PHA-activated enriched CD4+ T lymphocytes (CCR5+/+) were
obtained and cultured as described earlier (Nabatov et al., 2006). The
Raji cell line from the American Type Culture Collection (ATCC;
Rockville, MD, USA), and the Raji cell line expressing DC-SIGN (Raji-
DC-SIGN), were utilized in this study in transmission assay. Raji
transfectants expressing DC-SIGN were utilized in DC-SIGN mediated
binding experiments. Jurkat cells expressing CCR5 were generated by
retroviral transduction with lentiviral vectors.
Viruses
Replication-competent HIV-1 stocks were generated by the
passage of viruses through CD4+ lymphocytes, with tissue culture
infectious dose (TCID50/ml) determined by limiting dilution on CD4+-
enriched lymphocytes. Subtype B molecular cloned viruses JR-CSF
(R5) was used in the experiments.
Other replication-competent R5 HIV-1 viruses (gp120 from Bal
strain) expressing GFP in the infected cells were generated by
transfecting 293T cells with NL4.3eGFP-BaL proviral DNA plasmids
(9μg) together with VSV-G envelope plasmid (1μg). The plasmids
were generously provided by C. Aiken: pNL4.3eGFP-BaL, in which
wild-type NL4.3 envelope was switched for the R5 BaL envelope and
which encodes the GFP gene instead of the Nef gene. At day 2, VSV-G
pseudotyped viruses were harvested and used to acutely infect Jurkat
T cells. Two days post-infection, de novo viruses produced from Jurkat
T cells were harvested, run over a 0.22μm ﬁlter and frozen for future
use. Amounts of viruses produced were quantiﬁed by measuring
amounts of viral capsid in the supernatant of transfected Jurkat T cells
by p24 ELISA (Perkin Elmer Life Sciences, Walthem, MA, USA). An HIV-
1 input corresponding to 30ng was used. The level of HIV-1 infection
among the cells was assessed by ﬂow cytometry.
DC–mediated HIV-1 transmission assay
Immature DCs were plated at 4x104 cells/well in a 96-well format
and pulsed with the appropriate virus. After incubation, cells were
washed with culture medium before addition of CD4+-enriched T
lymphocytes at a concentration of 2x105 cells/well with a ﬁnal
volume of 200μl. The infectionwas followed with HIV-1 CA-p24 ELISA
or ﬂow cytometry. Infectious doses of 50 per well were used. The
inhibitory effects of Mermaid on the DC-mediated HIV-1 transfer to T
cells cultures was determined by preincubation of the virus with
mermaid for 30min at 37°C. As a control, normal virus was also placed
at 37°C. For experiments with mannan, both DCs and mermaid were
preincubated for 30min at 37°C with mannan (0.5mg/ml) and
subsequently used in experiments. Experiments were performed in
triplicates two times in independent experiments. The results were
plotted as medians of data for three samples with bars reﬂecting
standard deviation (SD).
Apoptosis detection assay
DCs and CD4+ T cells were cultured in the presence of 20μg/ml of
mermaid for 48days. The cells cultured in absence of mermaid were
used as a control. The apoptosis was monitored using the number of
dead cells according to forward and side scatters of FACS analysis
and the staining with DNA incorporating dye, namely 7-aminoacti-micin D (7-AAD; Invitrogen). 10μg/ml 7-AAD was added prior to
measurement. The staining was assessed by ﬂow cytometry (FACS
Calibur, BD Biosciences).
Statistical analyses
Students T-test and ANOVA in the case of normal distributed data
were used to analyse signiﬁcant differences between sets of data.
Data are presented as mean±SD with P valuesb0.05 (paired, two-
sided) considered as statistically signiﬁcant. The brackets and asterix
in the ﬁgures represent the statistical differences between the values:
d*T corresponds to Pb0.05, d**T to 0b0.01 and d***T to Pb0.001.
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